Grifols S.A. ADR Stock
Grifols S.A. ADR Stock
Grifols S.A. ADR took a tumble today and lost -€0.250 (-3.250%).
Pros and Cons of Grifols S.A. ADR in the next few years
Pros
?
M***** P*******
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Cons
?
B****
?
S********** s********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Grifols S.A. ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Grifols S.A. ADR | -3.250% | -1.911% | 0.654% | 14.074% | 1.316% | -10.983% | -51.055% |
| Beximco Pharmaceuticals Ltd. GDR | - | 0.000% | 0.000% | 11.628% | 7.143% | -11.111% | -60.000% |
| Eledon Pharmaceuticals Inc. | 3.140% | 15.217% | 12.766% | -56.793% | 24.219% | -37.402% | -86.387% |
| SELLAS Life Sciences Group Inc | -2.810% | 2.020% | 103.864% | 293.653% | 24.691% | 37.978% | -29.272% |
Comments
Grifols, S.A. (NASDAQ: GRFS) was upgraded by analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating.
Show more
Ratings data for GRFS provided by MarketBeat
Grifols, S.A. (NASDAQ: GRFS) was downgraded by analysts at Wall Street Zen from a "strong-buy" rating to a "buy" rating.
Show more
Ratings data for GRFS provided by MarketBeat
Grifols, S.A. (NASDAQ: GRFS) is now covered by analysts at Morgan Stanley. They set an "overweight" rating on the stock.
Show more
Ratings data for GRFS provided by MarketBeat